Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 with Pyrotinib and Bevacizumab in Breast Cancer Brain Metastasis
NCT06718933Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Fudan University. Started Jan 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06718933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718933.